Ligand partner SAGE Therapeutics receives fast track designation for SAGE-547
Ligand partner Sage Therapeutics announced the FDA has granted fast track designation to the SAGE-547 development program. SAGE-547 is an allosteric modulator of GABAA receptors in development for treatment of adult patients with refractory status epilepticus. July 22, 2014